Year 2023 / Volume 115 / Number 6
Original
Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis

306-314

DOI: 10.17235/reed.2022.9264/2022

Cong Dai, Zi-Yuan Dong, Yi-Nuo Wang, Yu-Hong Huang, Min Jiang,

Abstract
Background: There are concerns regarding the effect of biological agents on SARS-CoV-2 vaccination in patients with inflammatory bowel disease (IBD). A systematic review and meta-analysis was performed about the serological responses, breakthrough infections and clinical relapse of IBD patients treated with biological agents following SARS-CoV-2 vaccination. Methods: Electronic databases were searched to identify relevant studies. Primary outcomes were the pooled seroconversion rates, breakthrough infection rates and clinical relapse rates after SARS-CoV-2 vaccination in IBD patients treated with biological agents. Secondary outcomes were the comparison of seroconversion rates, breakthrough infection rates and clinical relapse rates in IBD patients treated with biological agents and control cohort after SARS-CoV-2 vaccination. Results: Thirty-five studies were included in this meta-analysis. A high percentage of seroconversion (96.6%, 99% and 99.2%) was achieved in IBD patients treated with anti-TNF-α therapy, vedolizumab and ustekinumab after SARS-CoV-2 vaccination, respectively. The pooled breakthrough infection rate was 2.5% and 3.9% in IBD patients treated with anti-TNF-α therapy and vedolizumab, respectively. The breakthrough infection rate in IBD patients treated with anti-TNF-α therapy was significantly lower than control cohort (RR 0.178, 95% CI 0.084–0.378). The pooled clinical relapse rate in IBD patients treated with anti-TNF-α therapy, vedolizumab and ustekinumab was 6.9%, 5.4% and 5.3%, respectively. Conclusion: The overall seroconversion rate after SARS-CoV-2 vaccination in IBD patients treated with biological agents is high. The overall breakthrough infection rate and clinical relapse rate in IBD patients treated with biological agents were low.
Lay Summary
There are concerns regarding the effect of biological agents on SARS-CoV-2 vaccination in patients with inflammatory bowel disease. We performed a systematic review and meta-analysis about the serological responses, breakthrough infections and clinical relapse of inflammatory bowel disease patients treated with biological agents including anti-TNF-α therapy, vedolizumab, and ustekinumab following SARS-CoV-2 vaccination. Thirty-five studies were included in this meta-analysis. A high percentage of seroconversion (96.6%, 99% and 99.2%) was achieved in inflammatory bowel disease patients treated with anti-TNF-α therapy, vedolizumab, and ustekinumab after SARS-CoV-2 vaccination respectively. The pooled breakthrough infection rate was 2.5% and 3.9% in inflammatory bowel disease patients treated with anti-TNF-α therapy and vedolizumab respectively. The pooled clinical relapse rate in inflammatory bowel disease patients treated with anti-TNF-α therapy, vedolizumab and ustekinumab was 6.9%, 5.4% and 5.3% respectively. Our study found that the overall seroconversion rate after SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with biological agents is high. The overall breakthrough infection rate and clinical relapse rate in IBD patients treated with biological agents were low.
Share Button
New comment
Comments
No comments for this article
References
1. Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2021.
DOI: 10.1136/postgradmedj-2021-140654
2. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev. 2021:102927.
DOI: 10.1016/j.autrev.2021.102927
3. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66.
DOI: 10.1038/s41575-020-00360-x
4. Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022;7(4):342-352.
DOI: 10.1016/S2468-1253(22)00005-X
5. Queiroz NSF, Teixeira FV, Freire CCF, et al. Brazilian Ibd Study Group Position Statement on Sars-Cov2 Vaccination. Arq Gastroenterol. 2021;58(1):1-4.
DOI: 10.1590/s0004-2803.202100000-02
6. Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6(3):218-224.
DOI: 10.1016/S2468-1253(21)00024-8
7. Eder P, Lodyga M, Dobrowolska A, Regula J, Rydzewska G. Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases. Prz Gastroenterol. 2021;16(1):2-4.
DOI: 10.5114/pg.2021.103666
8. Siegel CA, Melmed GY, McGovern DP, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635-640.
DOI: 10.1136/gutjnl-2020-324000
9. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884-1893.
DOI: 10.1136/gutjnl-2021-324789
10. Ben-Tov A, Banon T, Chodick G, Kariv R, Assa A, Gazit S. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign. Gastroenterology. 2021.
DOI: 10.1053/j.gastro.2021.06.076
11. Boland BS, Goodwin B, Zhang Z, et al. Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Inflammatory Bowel Disease Patients on Immune-Modulating Therapies. Clin Transl Gastroenterol. 2022.
DOI: 10.14309/ctg.0000000000000484
12. Caldera F, Knutson KL, Saha S, et al. Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. Am J Gastroenterol. 2021.
DOI: 10.14309/ajg.0000000000001570
13. Cannatelli R, Ferretti F, Carmagnola S, et al. Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD. Gut. 2021.
DOI: 10.1136/gutjnl-2021-326237
14. Cerna K, Duricova D, Lukas M, et al. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Inflamm Bowel Dis. 2021.
DOI: 10.1093/ibd/izab301
15. Chanchlani N, Lin S, Chee D, et al. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis. 2022;16(3):389-397
DOI: 10.1093/ecco-jcc/jjab153
16. Charilaou P, Tricarico C, Battat R, Scherl EJ, Longman RS, Lukin DJ. Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination. Clin Gastroenterol Hepatol. 2021.
DOI: 10.1016/j.cgh.2021.12.007
17. Dailey J, Kozhaya L, Dogan M, et al. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021.
18. Deepak P, Kim W, Paley MA, et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med. 2021;174(11):1572-1585.
DOI: 10.7326/M21-1757
19. Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFalpha. Gastroenterology. 2022;162(2):454-467.
DOI: 10.1053/j.gastro.2021.10.029
20. Frey S, Chowdhury R, Connolly CM, Werbel WA, Segev DL, Parian AM. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022.
DOI: 10.1016/j.cgh.2021.12.045
21. Garrido I, Lopes S, Macedo G. "Safety of COVID-19 vaccination in inflammatory bowel disease patients on biologic therapy". J Crohns Colitis. 2021.
DOI: 10.1093/ecco-jcc/jjab189
Related articles

Original

Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease

DOI: 10.17235/reed.2024.10305/2024

Letter

Strongyloides stercoralis hyperinfection presenting pneumatosis intestinalis and acute respiratory distress syndrome after treatment for COVID-19

DOI: 10.17235/reed.2024.10292/2024

Letter

Intestinal stenosis developed after a complete response to chemotherapy in a patient with Crohn’s disease and lymphoma of the jejunum

DOI: 10.17235/reed.2023.10004/2023

Letter

Vancomycin in the treatment of inflammatory bowel disease: there is a role beyond Clostridioides difficile infection

DOI: 10.17235/reed.2023.9942/2023

Original

Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life

DOI: 10.17235/reed.2023.9935/2023

Special Article

Activity of Spanish gastroenterology units before and after the COVID-19 pandemic: an assessment using the EFIC_AD tool, developed by the Sociedad Española de Patología Digestiva (SEPD)

DOI: 10.17235/reed.2023.9860/2023

Letter

Is cervical dysplasia a major concern in females with inflammatory bowel disease? A Spanish retrospective study

DOI: 10.17235/reed.2023.9890/2023

Original

FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients

DOI: 10.17235/reed.2024.9811/2023

Original

Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2023.9808/2023

Letter

Is post COVID-19 cholangiopathy an appropriate indication for liver transplantation?

DOI: 10.17235/reed.2023.9740/2023

Letter

Efficacy and safety of intravenous ustekinumab maintenance therapy in Crohn’s disease.

DOI: 10.17235/reed.2023.9594/2023

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Letter

Retractions relevant to COVID-19: does the retraction rate jump during the pandemic?

DOI: 10.17235/reed.2023.9549/2023

Original

Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis

DOI: 10.17235/reed.2023.9537/2023

Original

Fecal immunochemical test for hemoglobin versus fecal calprotectin to monitor endoscopic activity in inflammatory bowel disease

DOI: 10.17235/reed.2023.9536/2023

Original

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

DOI: 10.17235/reed.2023.9491/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Editorial

Relevance of patient-reported outcome measures (PROM) and patient-reported experience measures (PREM) to assess disease status and quality of care in patients with inflammatory bowel disease

DOI: 10.17235/reed.2023.9563/2022

Letter

Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents

DOI: 10.17235/reed.2023.9438/2022

Letter

Henoch-Schönlein purpura masquerading as Crohn’s disease flare

DOI: 10.17235/reed.2022.9414/2022

Original

Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study

DOI: 10.17235/reed.2023.9402/2022

Letter

SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence

DOI: 10.17235/reed.2023.9347/2022

Letter

Prediagnosis of soft tissue infection that was finally diagnosed as pyoderma gangrenosum of ulcerative colitis

DOI: 10.17235/reed.2022.9332/2022

Digestive Diseases Image

Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy

DOI: 10.17235/reed.2022.9218/2022

Letter

Successful treatment of Crohn’s disease, aseptic liver abscess and psoriasis with ustekinumab

DOI: 10.17235/reed.2022.9155/2022

Letter

Crohn’s disease induced by ocrelizumab in a patient with multiple sclerosis

DOI: 10.17235/reed.2022.9152/2022

Letter

Varicella zoster virus encephalitis: a potentially serious complication during treatment with vedolizumab

DOI: 10.17235/reed.2022.9121/2022

Original

Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

DOI: 10.17235/reed.2022.9101/2022

Letter

Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients

DOI: 10.17235/reed.2022.9058/2022

Review

“Out of the box” new therapeutic strategies for Crohn´s disease: moving beyond biologics

DOI: 10.17235/reed.2022.9010/2022

Letter

The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: a retrospective cohort study

DOI: 10.17235/reed.2022.9006/2022

Letter

Acute gastrointestinal graft-versus-host disease with cytomegalovirus and Epstein-Barr virus superinfection in a patient with COVID-19

DOI: 10.17235/reed.2022.9001/2022

Letter

Infection with SARS-CoV-2 as a potential achalasia trigger

DOI: 10.17235/reed.2022.8975/2022

Letter

Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment

DOI: 10.17235/reed.2022.8964/2022

Digestive Diseases Image

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Review

Efficacy and safety of fecal microbiota transplant for recurrent Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.8814/2022

Letter

One appendix too many: a severe IBD-U case in remission after appendectomy

DOI: 10.17235/reed.2022.8809/2022

Original

Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach

DOI: 10.17235/reed.2022.8781/2022

Letter

Combined aortic mural thrombi and limb ischemia in inflammatory bowel disease – A rare vascular manifestation

DOI: 10.17235/reed.2022.8774/2022

Letter

Impact of the SARS-CoV-2 pandemic on pancreatic cancer: diagnosis and short-term survival

DOI: 10.17235/reed.2022.8772/2022

Letter

Surgical acute abdomen and COVID-19 vaccination

DOI: 10.17235/reed.2022.8721/2022

Original

Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak

DOI: 10.17235/reed.2022.8668/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

Emergency endoscopy in pediatrics during the SARS-CoV-2 pandemic in a tertiary center – A changing pattern?

DOI: 10.17235/reed.2021.8532/2021

Letter

Experience with ustekinumab in reservoir Crohn's disease

DOI: 10.17235/reed.2021.8457/2021

Original

A slowdown of hepatitis C diagnosis in high-prevalence groups and with decentralized diagnostic strategies during the COVID-19 pandemic

DOI: 10.17235/reed.2022.8412/2021

Letter

Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center

DOI: 10.17235/reed.2021.8397/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Original

Impact of the COVID-19 pandemic on digestive endoscopists: an Ibero-American study

DOI: 10.17235/reed.2022.8327/2021

Letter

Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results

DOI: 10.17235/reed.2021.8320/2021

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Letter

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Original

Impact of the COVID-19 pandemic on endoscopic retrograde cholangiopancreatography: a single center experience

DOI: 10.17235/reed.2021.8229/2021

Letter

Diagnosis of synchronous pancreatic and ampullary adenocarcinomas during the COVID-19 pandemic

DOI: 10.17235/reed.2021.8212/2021

Letter

Comparison of satisfaction degree of patients treated at the Inflammatory Bowel Disease Unit (IBDU) of Hospital Universitario 12 de Octubre between previous face-to-face care and telephone care during the COVID-19 pandemic

DOI: 10.17235/reed.2021.8185/2021

Letter

Gastroduodenal ischemia in a patient with severe SARS-CoV-2 infection

DOI: 10.17235/reed.2021.8178/2021

Original

Impact of the COVID-19 lockdown on liver transplant recipients. A single center observational study

DOI: 10.17235/reed.2021.8173/2021

Digestive Diseases Image

Portal thrombosis in a patient with SARS-CoV-2 infection

DOI: 10.17235/reed.2021.8099/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Original

Mild AST elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort

DOI: 10.17235/reed.2021.8007/2021

Original

Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

DOI: 10.17235/reed.2021.8003/2021

Letter

SARS-CoV-2 and splenic infarction: a rarely described thromboembolic presentation

DOI: 10.17235/reed.2021.7964/2021

Letter

Assessment of liver damage in patients with COVID-19 is sub-optimal: results of a survey of medical practitioners

DOI: 10.17235/reed.2021.7970/2021

Letter

ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation

DOI: 10.17235/reed.2021.7921/2021

Original

Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes

DOI: 10.17235/reed.2021.7915/2021

Letter

COVID-19 and venous thromboembolism: part of a multisystem disease

DOI: 10.17235/reed.2021.7907/2021

Letter

Pneumoperitoneum and COVID-19. A causal association?

DOI: 10.17235/reed.2021.7877/2021

Letter

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Letter

Pneumatosis intestinalis as an incidental finding in a patient with COVID-19 infection

DOI: 10.17235/reed.2021.7857/2021

Letter

Acute pancreatitis related to SARS-CoV-2 infection. Disclaimer

DOI: 10.17235/reed.2021.7853/2021

Letter

Hepatic injury and COVID-19: pathogenic mechanisms or epiphenomena?

DOI: 10.17235/reed.2021.7851/2021

Original

Abnormal liver chemistry constitutes an independent prognostic factor of less favorable clinical course in patients with COVID-19

DOI: 10.17235/reed.2021.7842/2021

Letter

Pancreatic injury and acute pancreatitis in COVID-19 patients

DOI: 10.17235/reed.2021.7807/2021

Letter

Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis

DOI: 10.17235/reed.2021.7768/2020

Letter

Acute pancreatitis in SARS-CoV-2 infection. Beyond respiratory distress

DOI: 10.17235/reed.2021.7781/2020

Editorial

COVID-19 and the digestive system: implications for transforming care delivery

DOI: 10.17235/reed.2021.7774/2020

Letter

The COVID-19 pandemic shows us in which way the care of patients with inflammatory bowel disease should move

DOI: 10.17235/reed.2021.7765/2020

Original

Risk of COVID-19 transmission in esophageal, anorectal manometry and 24-hour impedance-pH monitoring

DOI: 10.17235/reed.2021.7767/2020

Original

Gastric ulcers with upper gastrointestinal bleeding in patients with severe SARS-CoV-2

DOI: 10.17235/reed.2021.7759/2020

Letter

Safety in digestive endoscopy during the ongoing COVID-19 pandemic

DOI: 10.17235/reed.2021.7748/2020

Editorial

Leading in turbulent times with the aim to serve

DOI: 10.17235/reed.2020.7684/2020

Original

Resumption of endoscopy in the Galician colorectal cancer screening programme after the COVID-19 lock down: patient safety results

DOI: 10.17235/reed.2020.7647/2020

Original

Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

DOI: 10.17235/reed.2021.7638/2020

Original

Poor agreement between clinical screening and universal pre-procedure SARS-CoV-2 PCR testing prior to endoscopy

DOI: 10.17235/reed.2021.7612/2020

Digestive Diseases Image

Spontaneous pneumoperitoneum and pneumatosis intestinalis as sole manifestations of a COVID-19 infection. An extremely rare complication

DOI: 10.17235/reed.2020.7601/2020

Letter

Patients with upper gastrointestinal foreign bodies are more likely to consult later and with a higher rate of hospitalization during the COVID-19 pandemic

DOI: 10.17235/reed.2020.7593/2020

Letter

Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic

DOI: 10.17235/reed.2020.7562/2020

Letter

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Original

Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit

DOI: 10.17235/reed.2020.7543/2020

Letter

A case of severe diverticulosis in a patient with ulcerative colitis

DOI: 10.17235/reed.2020.7529/2020

Review

The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease

DOI: 10.17235/reed.2020.7499/2020

Letter

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Original

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

DOI: 10.17235/reed.2020.7472/2020

Original

The impact of SARS-CoV-2 infection on the surgical management of colorectal cancer: lessons learned from a multicenter study in Spain

DOI: 10.17235/reed.2020.7460/2020

Letter

Intestinal obstruction secondary to Crohn-like disease in common variable immu-nodeficiency

DOI: 10.17235/reed.2020.7440/2020

Original

Pre-procedural antibody testing for SARS-CoV-2 in the routine endoscopic practice

DOI: 10.17235/reed.2020.7434/2020

Letter

Latin American authorship in scientific production on COVID-19

DOI: 10.17235/reed.2020.7432/2020

Original

Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center

DOI: 10.17235/reed.2020.7431/2020

Original

Evaluation of epicardial adipose tissue and carotid intima-media thickness as a marker of atherosclerosis in patients with inflammatory bowel disease

DOI: 10.17235/reed.2020.7394/2020

Review

Impact of liver injury on the severity of COVID-19: a systematic review with meta-analysis

DOI: 10.17235/reed.2020.7397/2020

Editorial

Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity

DOI: 10.17235/reed.2020.7512/2020

Original

Evaluation of endoscopy requests in the resumption of activity during the SARS-CoV-2 pandemic: denial of nonindicated requests and prioritization of accepted requests

DOI: 10.17235/reed.2020.7375/2020

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Original

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response

DOI: 10.17235/reed.2020.7352/2020

Letter

Resuming ultrasound activity after the acute phase of the COVID-19 pandemic

DOI: 10.17235/reed.2020.7343/2020

Original

Severe colon ischemia in patients with severe coronavirus-19 (COVID-19)

DOI: 10.17235/reed.2020.7329/2020

Letter

Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19

DOI: 10.17235/reed.2020.7297/2020

Letter

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Letter

Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease: the extrapolation concept

DOI: 10.17235/reed.2020.7253/2020

Original

Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses

DOI: 10.17235/reed.2020.7230/2020

Original

Ustekinumab treatment for toxic megacolon in severe colonic Crohn’s disease

DOI: 10.17235/reed.2020.7228/2020

Letter

Author´s answer to: “Effect of adacolumn® in ulcerative colitis with COVID-19”

DOI: 10.17235/reed.2020.7188/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Special Article

Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG

DOI: 10.17235/reed.2020.7141/2020

Rapid reviews

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Original

Vedolizumab response in inflammatory bowel disease. Two years of follow-up

DOI: 10.17235/reed.2020.7130/2020

Review

COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic

DOI: 10.17235/reed.2020.7128/2020

Review

Vitamin D and inflammatory bowel disease: what do we know so far?

DOI: 10.17235/reed.2020.7061/2020

Special Article

Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18)

DOI: 10.17235/reed.2020.7052/2020

Original

Normalization of long-term quality of life in Crohn’s disease patients receiving ustekinumab

DOI: 10.17235/reed.2020.6941/2020

Original

Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases

DOI: 10.17235/reed.2020.6938/2020

Letter

Gastrointestinal tuberculosis, the great simulator. From inflammatory disease to a tumor

DOI: 10.17235/reed.2020.6934/2020

Original

Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

DOI: 10.17235/reed.2020.6857/2020

Original

Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

DOI: 10.17235/reed.2020.6847/2019

Letter

Vedolizumab-associated psoriasis: until where does gut selectivity go?

DOI: 10.17235/reed.2020.6817/2019

Letter

An acute episode of inflammatory bowel disease vs a rare manifestation of an Epstein-Barr virus-positive mucocutaneous ulcer. Case report

DOI: 10.17235/reed.2020.6737/2019

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn’s disease: an observational study

DOI: 10.17235/reed.2020.6693/2019

Original

Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients

DOI: 10.17235/reed.2020.6677/2019

Original

Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit

DOI: 10.17235/reed.2020.6620/2019

Original

Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

DOI: 10.17235/reed.2020.6618/2019

Original

Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts

DOI: 10.17235/reed.2020.6552/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Original

Status of transition care in inflammatory bowel disease in Spain. Different medical perspectives

DOI: 10.17235/reed.2019.6310/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Original

The main determinants of disability in IBD and its relationship to optimism

DOI: 10.17235/reed.2019.6033/2018

Original

Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors

DOI: 10.17235/reed.2019.6029/2018

Letter

A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn’s disease

DOI: 10.17235/reed.2019.5990/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Letter

Intravenous ustekinumab reinduction as a Crohn’s disease rescue strategy following a secondary non-response

DOI: 10.17235/reed.2019.5802/2018

Original

The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease

DOI: 10.17235/reed.2019.5797/2018

Original

Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity

DOI: 10.17235/reed.2018.5714/2018

Letter

Sweet syndrome after treatment with vedolizumab in a patient with Crohn’s disease

DOI: 10.17235/reed.2018.5603/2018

Original

Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.5600/2018

Original

The association between de novo inflammatory bowel disease and celiac disease

DOI: 10.17235/reed.2019.5535/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Original

A meta-analysis of dietary carbohydrate intake and inflammatory bowel disease risk: evidence from 15 epidemiology studies

DOI: 10.17235/reed.2018.5490/2018

Letter to the Editor

Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease

DOI: 10.17235/reed.2018.5456/2018

Original

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

DOI: 10.17235/reed.2018.5368/2017

Original

Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the “Gestiona hierro-EII” survey

DOI: 10.17235/reed.2018.5354/2017

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Original

Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index

DOI: 10.17235/reed.2017.5137/2017

Editorial

The complexity of evaluating and increasing adherence in inflammatory bowel disease

DOI: 10.17235/reed.2017.5143/2017

Case Report

Serrated polyposis syndrome associated with long-standing inflammatory bowel disease

DOI: 10.17235/reed.2017.5068/2017

Case Report

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis

DOI: 10.17235/reed.2017.5024/2017

Letter to the Editor

Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis

DOI: 10.17235/reed.2017.4941/2017

Original

Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease

DOI: 10.17235/reed.2017.4845/2017

Case Report

Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease

DOI: 10.17235/reed.2017.4819/2016

Original

Epidemiology of inflammatory bowel disease in Málaga: incidence rate and follow-up of a cohort diagnosed between 2007-2008

DOI: 10.17235/reed.2017.4708/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Letter to the Editor

Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis

DOI: 10.17235/reed.2017.4564/2016

Original

The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis

DOI: 10.17235/reed.2016.4470/2016

Original

Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease

DOI: 10.17235/reed.2016.4447/2016

Original

Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization

DOI: 10.17235/reed.2016.4440/2016

Original

How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey

DOI: 10.17235/reed.2016.4410/2016

Letter to the Editor

Pharmaceutical costs for inflammatory bowel disease units — An issue for department heads? The GESTIONAEII survey

DOI: 10.17235/reed.2016.4192/2016

Original

Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease

DOI: 10.17235/reed.2015.3954/2015

Letter to the Editor

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

DOI: 10.17235/reed.2015.3978/2015

Case Report

Immmunodeficiencies and autoimmune diseases: common variable immunodeficiency and Crohn-like

DOI: 10.17235/reed.2015.3872/2015

Citation tools
Dai C, Dong Z, Wang Y, Huang Y, Jiang M. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. 9264/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1387 visits.
This article has been downloaded 66 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 06/10/2022

Accepted: 02/11/2022

Online First: 10/11/2022

Published: 06/06/2023

Article revision time: 15 days

Article Online First time: 35 days

Article editing time: 243 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology